Survival of patients with severe congestive heart failure treated with oral milrinone

D. S. Baim, W. S. Colucci, E. Scott Monrad, H. S. Smith, R. F. Wright, A. Lanoue, D. F. Gauthier, B. J. Ransil, W. Grossman, E. Braunwald

Research output: Contribution to journalArticle

100 Citations (Scopus)

Abstract

The safety and efficacy of long-term oral milrinone therapy were evaluated overa a 2 1/2 year period in 100 patients who had severe congestive heart failure despite conventional therapy. Long-term oral milrinone therapy (27 ± 8 mg/day initial dose) was well tolerated; drug-related side effects occurred in only 11% of patients and led to drug withdrawal in only 4% of patients. Of 94 patients evaluated after 1 month of therapy, 51% had improved by at least one New York Heart Association functional class. Despite hemodynamic and clinical improvements, life table analysis showed a 39% mortality rate at 6 months and a 63% mortality rate at 1 year of therapy. Characteristics at study entry that predicted death within 6 months included more advanced functional class, impaired renal function, lower right ventricular ejection fraction, presence of nonsustained ventricular tachycardia on 24 hour ambulatory electrocardiography, more impaired baseline hemodynamic function and absence of clinical improvement after 1 month of milrinone therapy. Multivariate analysis selected lower baseline cardiac index and aortic systolic pressure as the most significant variables in predicting death; patients who died of progressive heart failure had less frequent use of antiarrhythmic drugs and greater increases in furosemide and milrinone doses during long-term follow-up than did those who died suddenly. Thus, although milrinone is well tolerated and produces early symptomatic benefits in approximately half of patients with congestive heart failure refractory to conventional therapy, there is no evidence that it improves the high baseline mortality in this disorder.

Original languageEnglish (US)
Pages (from-to)661-670
Number of pages10
JournalJournal of the American College of Cardiology
Volume7
Issue number3
StatePublished - 1986
Externally publishedYes

Fingerprint

Milrinone
Heart Failure
Survival
Therapeutics
Mortality
Hemodynamics
Ambulatory Electrocardiography
Life Tables
Anti-Arrhythmia Agents
Furosemide
Ventricular Tachycardia
Drug-Related Side Effects and Adverse Reactions
Stroke Volume
Arterial Pressure
Multivariate Analysis
Blood Pressure
Kidney
Safety

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Baim, D. S., Colucci, W. S., Monrad, E. S., Smith, H. S., Wright, R. F., Lanoue, A., ... Braunwald, E. (1986). Survival of patients with severe congestive heart failure treated with oral milrinone. Journal of the American College of Cardiology, 7(3), 661-670.

Survival of patients with severe congestive heart failure treated with oral milrinone. / Baim, D. S.; Colucci, W. S.; Monrad, E. Scott; Smith, H. S.; Wright, R. F.; Lanoue, A.; Gauthier, D. F.; Ransil, B. J.; Grossman, W.; Braunwald, E.

In: Journal of the American College of Cardiology, Vol. 7, No. 3, 1986, p. 661-670.

Research output: Contribution to journalArticle

Baim, DS, Colucci, WS, Monrad, ES, Smith, HS, Wright, RF, Lanoue, A, Gauthier, DF, Ransil, BJ, Grossman, W & Braunwald, E 1986, 'Survival of patients with severe congestive heart failure treated with oral milrinone', Journal of the American College of Cardiology, vol. 7, no. 3, pp. 661-670.
Baim, D. S. ; Colucci, W. S. ; Monrad, E. Scott ; Smith, H. S. ; Wright, R. F. ; Lanoue, A. ; Gauthier, D. F. ; Ransil, B. J. ; Grossman, W. ; Braunwald, E. / Survival of patients with severe congestive heart failure treated with oral milrinone. In: Journal of the American College of Cardiology. 1986 ; Vol. 7, No. 3. pp. 661-670.
@article{d91c16a11d904d39b19b286c96ae85c1,
title = "Survival of patients with severe congestive heart failure treated with oral milrinone",
abstract = "The safety and efficacy of long-term oral milrinone therapy were evaluated overa a 2 1/2 year period in 100 patients who had severe congestive heart failure despite conventional therapy. Long-term oral milrinone therapy (27 ± 8 mg/day initial dose) was well tolerated; drug-related side effects occurred in only 11{\%} of patients and led to drug withdrawal in only 4{\%} of patients. Of 94 patients evaluated after 1 month of therapy, 51{\%} had improved by at least one New York Heart Association functional class. Despite hemodynamic and clinical improvements, life table analysis showed a 39{\%} mortality rate at 6 months and a 63{\%} mortality rate at 1 year of therapy. Characteristics at study entry that predicted death within 6 months included more advanced functional class, impaired renal function, lower right ventricular ejection fraction, presence of nonsustained ventricular tachycardia on 24 hour ambulatory electrocardiography, more impaired baseline hemodynamic function and absence of clinical improvement after 1 month of milrinone therapy. Multivariate analysis selected lower baseline cardiac index and aortic systolic pressure as the most significant variables in predicting death; patients who died of progressive heart failure had less frequent use of antiarrhythmic drugs and greater increases in furosemide and milrinone doses during long-term follow-up than did those who died suddenly. Thus, although milrinone is well tolerated and produces early symptomatic benefits in approximately half of patients with congestive heart failure refractory to conventional therapy, there is no evidence that it improves the high baseline mortality in this disorder.",
author = "Baim, {D. S.} and Colucci, {W. S.} and Monrad, {E. Scott} and Smith, {H. S.} and Wright, {R. F.} and A. Lanoue and Gauthier, {D. F.} and Ransil, {B. J.} and W. Grossman and E. Braunwald",
year = "1986",
language = "English (US)",
volume = "7",
pages = "661--670",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "3",

}

TY - JOUR

T1 - Survival of patients with severe congestive heart failure treated with oral milrinone

AU - Baim, D. S.

AU - Colucci, W. S.

AU - Monrad, E. Scott

AU - Smith, H. S.

AU - Wright, R. F.

AU - Lanoue, A.

AU - Gauthier, D. F.

AU - Ransil, B. J.

AU - Grossman, W.

AU - Braunwald, E.

PY - 1986

Y1 - 1986

N2 - The safety and efficacy of long-term oral milrinone therapy were evaluated overa a 2 1/2 year period in 100 patients who had severe congestive heart failure despite conventional therapy. Long-term oral milrinone therapy (27 ± 8 mg/day initial dose) was well tolerated; drug-related side effects occurred in only 11% of patients and led to drug withdrawal in only 4% of patients. Of 94 patients evaluated after 1 month of therapy, 51% had improved by at least one New York Heart Association functional class. Despite hemodynamic and clinical improvements, life table analysis showed a 39% mortality rate at 6 months and a 63% mortality rate at 1 year of therapy. Characteristics at study entry that predicted death within 6 months included more advanced functional class, impaired renal function, lower right ventricular ejection fraction, presence of nonsustained ventricular tachycardia on 24 hour ambulatory electrocardiography, more impaired baseline hemodynamic function and absence of clinical improvement after 1 month of milrinone therapy. Multivariate analysis selected lower baseline cardiac index and aortic systolic pressure as the most significant variables in predicting death; patients who died of progressive heart failure had less frequent use of antiarrhythmic drugs and greater increases in furosemide and milrinone doses during long-term follow-up than did those who died suddenly. Thus, although milrinone is well tolerated and produces early symptomatic benefits in approximately half of patients with congestive heart failure refractory to conventional therapy, there is no evidence that it improves the high baseline mortality in this disorder.

AB - The safety and efficacy of long-term oral milrinone therapy were evaluated overa a 2 1/2 year period in 100 patients who had severe congestive heart failure despite conventional therapy. Long-term oral milrinone therapy (27 ± 8 mg/day initial dose) was well tolerated; drug-related side effects occurred in only 11% of patients and led to drug withdrawal in only 4% of patients. Of 94 patients evaluated after 1 month of therapy, 51% had improved by at least one New York Heart Association functional class. Despite hemodynamic and clinical improvements, life table analysis showed a 39% mortality rate at 6 months and a 63% mortality rate at 1 year of therapy. Characteristics at study entry that predicted death within 6 months included more advanced functional class, impaired renal function, lower right ventricular ejection fraction, presence of nonsustained ventricular tachycardia on 24 hour ambulatory electrocardiography, more impaired baseline hemodynamic function and absence of clinical improvement after 1 month of milrinone therapy. Multivariate analysis selected lower baseline cardiac index and aortic systolic pressure as the most significant variables in predicting death; patients who died of progressive heart failure had less frequent use of antiarrhythmic drugs and greater increases in furosemide and milrinone doses during long-term follow-up than did those who died suddenly. Thus, although milrinone is well tolerated and produces early symptomatic benefits in approximately half of patients with congestive heart failure refractory to conventional therapy, there is no evidence that it improves the high baseline mortality in this disorder.

UR - http://www.scopus.com/inward/record.url?scp=0022636741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022636741&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 661

EP - 670

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 3

ER -